Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline), By Type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global peptide drug conjugates market size was valued at USD 596.27 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 18.58% from 2022 to 2030. The robust clinical trial pipeline with peptide drug conjugates (PDCs) coupled with increase in R&D investments for developing PDCs and rising disease burden across the globe are the factors expected to contribute to the market growth. For instance, in July 2021, Takeda Pharmaceutical Company Limited in collaboration with Peptide Dream, announced to invest USD 3.5 billion to develop peptide drugs for neuromuscular disease.

Pharmaceutical companies are developing PDCs as targeted therapeutic drugs for the metabolic diseases, Covid-19 viral diseases, and cancer among others. Currently, the market has presence of two FDA approved drugs Pepaxto (Melflufen) and Lutathera (Lu 177 dotatate) for cancer treatment. Therefore, rising prevalence of such diseases is driving the peptide drug conjugates market. According to National Cancer Institute, in 2020, more than 1.8 million new cancer cases and more than 600,000 deaths occurred in the U.S. due to the cancer.

The strong product pipeline and increasing financial investments in research and development is offering lucrative opportunity for the peptide drug conjugates market growth. For instance, Angio Chem, Inc.’s product candidate- ANG1005 indicated for brain tumor is undergoing phase 3 clinical studies, Bicycle Therapeutics pipeline products- BT5528&BT1718 indicated for non-small cell carcinoma, are under phase 2 clinical trials. Hence, the expected new PDC approval for treatment of multiple types of cancer will boost the market growth in near future.

According to the national cancer institute, there are more than 250 FDA approved chemotherapeutic drugs used in the treatment of malignant tumors. However, the major drawback associated with such small molecules is uncontrolled toxicity resulting into severe side effects. Moreover, increasing drug resistance of tumor cells to such agents has led to demand for the better treatment approach like targeted PDCs and thereby, driving the peptide drug conjugates space. However, low bioactivity, poor stability, long research and development time, and slow clinical development process as therapeutic agents of PDC is expected to restrain the segment, leading to increase in overall time and cost incurred for the development.

Product Insights

The Lutathera product segment dominated thepeptide drug conjugates market with a revenue share of 80.5% in 2021. The first FDA approved PDC is Novartis’s Lutathera (lutetium Lu 177), a radio labeled somatostatin analog which is an advanced accelerator injection. The expected patent expiry date is 25^th July 2038. Itis indicated for the treatment of somatostatin receptor-positive gastro enteropancreatic neuroendocrine tumors including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera consist of an amide linkage between homing peptide somatostatin and cytotoxic radiotherapeutic agent 177Lu.

Oncopeptides ABreceived FDA approval for its first-in-classpeptide-conjugated alkylator, Pepaxto (melflufen), in February 2021. The combination of Pepaxto (Melphalan flufenamide) with dexamethasone is indicated for the multiple myeloma in adult patients. The drug has demonstrated anti-myeloma activity in myeloma tumor cells resistant to bortezomib and the alkylator melphalan. Melflufen patents cover major markets in the US, Japan, Canada, and Europe. However, the drug has been withdrawn from the U.S. market in October 2021, based on overall survival data from its phase 3 study.

Type Insights

Therapeutic segment dominated the peptide drug conjugatesmarket with the revenue share of 82.3% in 2021 and is anticipated to witness the fastest growth. The factors attributing to dominance is the presence of both approved PDCs, Lutathera and Pepaxtoas therapeutic agents targeting tumor cells. Moreover, the presence of targeting therapeutic drugs such as ANG1005,

BT5528 and BT1718 under clinical trials are expected to boost the market during the forecast period. Along with cancer, pharmaceutical companies are developing targeting therapeutic PDCs for metabolic diseases and coronavirus diseases due to the significant benefits of PDCs in therapeutic segment.

PDCs coupled with radionucleotides, can also act as diagnostic agents. For example,Mallinckrodt Pharmaceuticals’ In-DTPA-octreotide (octreoscan) which contains radioactive nucleotide, primarily used in localization of neuroendocrine tumors. Furthermore, development and applications of PDCs in diagnosis is anticipated to offer remunerative opportunity for the segment growth.

Regional Insights

North America dominated the overall peptide drug conjugates (PDCs) market in terms of revenue share of 45.62% in 2021, owing to the launch of Melflufen and rapid uptake of PDC drugs in cancer therapy. Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive the market growth. Furthermore, rising cases of cancer and related mortality is fueling the market growth in the region. For instance, NCI reported approximately 1,806,590 new cancer cases and 606,520 disease related deaths in 2020.

Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period. Growth of the region is attributed to the upsurge in number of cancer cases and strategic initiatives undertaken by the market players for regional expansion in such regions. Furthermore, rising research and development along with increasing investments to develop and commercialize such novel delivery systems is anticipated to boost the market growth in the region.

Key Companies & Market Share Insights

Strategic collaborations are one of the key initiatives undertaken by the companies to gain market share. In November 2022, Cybrexa Therapeutics and Exelixis, Inc. announced the collaboration agreement providing Exelixis the right to acquire, first-in-class peptide-drug conjugate (PDC), CBX-12. This initiative is expected to expand its clinical pipeline for the targeted drug therapy.

Additionally, in June 2019, Novartis AG and PeptiDream Inc. collaborated to develop PDC, macrocyclic peptide for diagnostic and therapeutic applications. Such strategic initiatives by the key players are driving the market growth.Some of the prominent players in global peptide drug conjugates market include:

• Novartis AG

• Oncopeptides AB

• Bicycle Therapeutics

• AstraZeneca

• Cybrexa Therapeutics

• Angiochem Inc.

• Innovasium Soricimed Biopharma

• Theratechnologies

Peptide Drug Conjugates Market Report Scope

Global Peptide Drug Conjugates Market Segmentation

This report forecasts revenue growth at the global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global peptide drug conjugates market report based on the product, type, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Lutetium

  • Melflufen

  • ANG1005

  • BT1718

  • CBX-12

  • Other Pipeline Products

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Therapeutic

  • Diagnostic

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE